IFCCREGIONAL FEDERATIONS

REPRESENTATIVESNOMINATIONS

2018 - 2020

LIST OF CANDIDATES

Nominees Regional Federation

Adekunle Bashiru OKESINA

African Federation of Clinical Chemistry (AFCC)

HedhiliABDERRAZEK

Arab Federation of Clinical Biology (AFCB)

Sunil SETHI

Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)

Sverre SANDBERG

European Federation of Clinical Chemistry and Laboratory Medicine

Rosa SIERRA-AMOR

Latin-American Confederation of Clinical Biochemistry

To be nominated(no election will be held

for this position)

North American Federation of Clinical Chemistry and Laboratory Medicine

ADEKUNLE BASHIRU OKESINA

I am Professor Adekunle Bashiru Okesina, born on October 11th, 1954. I have decided to present myself to serve Africa for the period of three years from January 2018 to December 2020 as a member of IFCC Executive Board representing AFCC.

BRIEF CURRICULUM VITAEI, Professor Okesina, was former Vice-Chancellor, Osun State University Nigeria. Former Deputy Vice Chancellor and former Dean. I graduated with MBBS degree from the University of Lagos in 1980, Fellow of National Postgraduate Medical College of Nigeria (NPGMCN) in 1988 and that of W/African College of Physician (WACP) in Chemical Pathology in 1989. Foundation Fellow of College of Pathology of East Central and South Africa (COPECSA) in 2014. I did Clinical Attachment at the Institute of Neurology Queens Square London and East Surrey Hospital between 1987 and 1988. From 1991 to 1993 I was a Commonwealth Medical Research Fellow in Clinical Endocrinology at Hammersmith Hospital and Royal Postgraduate Medical College in London. I was appointed Lecturer 1 at the University of Ilorin in 1989, Reader in 1994 and full Professor in 2000. I was appointed Consultant Chemical Pathology Unilorin Teaching Hospital in 1989. I was visiting lecturer to University of Transkei (Walter Sisulu University) in South Africa between 1997 and 2000.

I am a Resource person for annual revision and update courses of NPGMCN and WACP since 1993. Member Faculty Board of Pathology from 1993 to 1997 and Member of Senate, NPGMCN from 2007 to 2011. I was Chairman Faculty of Pathology of West African College of Physicians from 2007 to 20011. I was Chief Examiner for Faculty of Pathology, WACP from 2011 to 2013.

I was the National President of Association of Clinical Chemists of Nigeria 2007 to 2016 and the President of the African Federation of Clinical Chemistry (AFCC) from 2013 to date. I have served as external examiner to many Universities in Nigeria and Africa, including, University of Lagos, Ibadan, Jos, Ahmadu Bello, Port Harcourt, Calabar, Cape Peninsula South Africa, Nairobi Kenya and Ghana. Also, a member of accreditation team to visit University of Ghana Teaching Hospital, University of Gambia Queens Hospital and many Universities and Teaching Hospitals in Nigeria.

I have over 80 publications in reputable journals both local and international. I have trained more than 14 specialists in Chemical Pathology out of which four have become Professors also some are Provosts and Deans in various Universities in Nigeria. My research interest is in diabetes mellitus and chronic non-communicable diseases. I am a charter member of Ilorin Central Lions where I received many National and International Awards for services to the community. I am proficient in written and spoken English, which is the only Official National Language of Nigeria.

AFRICAN FEDERATION OF CLINICAL CHEMISTRY (AFCC)

MY VISION AND MISSION AS MEMBER OF EXECUTIVE BOARDOn a regular basis, I will prepare a comprehensive report to be presented to the IFCC Executive Board on major activities and events taken place as it involves laboratory medicine services, training and human development in Africa.

The motivation of national societies in Africa to follow prepared strategic plan of AFCC. This will make them be more active. By so doing, image and activities of IFCC will be extended through these National Societies.

I will encourage more countries in Africa to form national associations that can become members of IFCC.

I will take advantage of my linkages with various part of Africa to harmonise and unify activities. Through West African College of Physicians, Faculty of Laboratory Medicine of which I am a Fellow and former Faculty Chairman and Chief Examiner, I will strengthen and enhance the involvement of IFCC activities in countries in West Africa. As a foundation Fellow of College of Pathology of ECSA, I will use the opportunity to increase communication and exchange of ideas between the two regions of African under the auspices of IFCC and by so doing improve quality and quantity of laboratory services in Africa. I must add that at a meeting in Uganda in 2015 which I attended the Royal College of Pathologist promised to fund a journal of pathology to be jointly administered by both colleges of East and West Africa , I have since secured the consent of Faculty of Laboratory Medicine in West Africa while I am waiting for response from our East African counterpart. I have established linkage with the University of Alexandria in Egypt through which more collaboration can be taking place between Arab Federation and AFCC. For example, I facilitated the move for Egon to assist Egypt in their conference on Quality Assurance early this year. I hope to do more of this in various parts of Africa. MoU with ASLM will be pushed beyond paper work into joint actions from the list of activities. I am also actively involved in the administration and examinations in the National Postgraduate Medical College of Nigeria where I have been Member of Senate and also of Faculty Board of Pathology. This will provide the opportunity for involvement in an activity that can be of benefit to Nigerian citizens in the area of laboratory and indeed health services.

My administrative experience will also be useful in providing adequate representation for Africa. The following will be my specific targets:a. Partnership with other associations to improve Quality Management System and establish

accreditation of laboratory services. Such bodies will include African Society for Laboratory Medicine (ASLM), National Postgraduate College of Nigeria, Association of Pathologists of Nigeria, Association of Medical Laboratory Scientists of Nigeria, Royal College of Pathology, WaSLAM, WHO, West African College of Physicians, COPECSA.

b. Advocacy for resources/funding towards the improvement of Medical Laboratory services, training and human development in Africa

c. Active mobilisation of young scientist from member countries who will serve as the foundation for sustainability of achievements in the area of laboratory medicine services provisions in Africa. The mentorship program will be used to create access to high-quality technical support.

SIGNEDProf Adekunle Bashiru Okesina. MBBS, FMCPath, FWACP, FCPath ECSA,

ASSOCIATION OF CLINICAL CHEMISTS OF NIGERIA(ACCN)

Our Ref__________ Your Ref__________ Date 21st June 2017

Executive Members

PresidentProf. E. O. Agbedana

Vice President Prof. J. E. Ahaneku

Secretary & IFCC National Representative

Dr. O. O. Soriyan

Asst. Secretary Dr. C. E. Ekene

Treasurer

Prof. O. O. Adedeji

Financial Secretary Dr. I. D. Nnakenyi

Auditor

Dr. O. O. Olawale

Public Relations Officer A. Ogunleye

Ex-OfficioProf. A. B. Okesina

Bernard Gouget,Chair, IFCC Nominations Committee,LETTER OF MOTIVATION IN SUPPORT OF THE APPLICATION OF PROF. ADEKUNLE

BASHIRU OKESINA FOR THE POST OF MEMBER OF EXECUTIVE BOARD OF IFCC REPRESENTING AFCC

On behalf of Association of Clinical Chemists of Nigeria (ACCN), I am most pleased to write in support of the application of Professor Adekunle Bashiru OKESINA for MEMBERSHIP OF EXECUTIVE BOARD OF IFCC. Professor Okesina has been an active and reliable member and indeed the immediate past President of the Association and current President of African Federation of Clinical Chemists (AFCC). Professor Okesina is a hardworking, dedicated, brilliant and very resourceful Laboratory Physician and scientist. He has an incredible capacity to cope with a large volume of work without any manifestation of fatigue. He demonstrates an excellent capacity of working independently as well as working with others as the leader or as an effective member of a team.His educational background is excellent. His professional exposures and experience in Nigeria and abroad are fantastic. Professor Okesina has won several academics distinctions and scholarships, including the Oyo State Merit Scholarship Award and the Commonwealth Medical Fellowship which he spent in Britain as a Medical Research Fellow. He is an accomplished Medical Doctor and outstanding Chemical Pathologist, a seasoned University Professor, a resourceful lecturer and a successful administrator. Professor Okesina is a meticulous researcher, a prolific writer who is very original with a very strong analytical ability. He has more than 80 publications in reputable national and international journals to his credit.Professor Okesina has considerable administrative and managerial exposure and experience up to the highest level in the University. He was Vice Chancellor, Deputy Vice Chancellor, a member of the Faculty Board of Postgraduate Medical College, Dean of Faculty of Basic Medical Sciences, Sub-Dean Clinicals, Faculty of Health Sciences, Head of Department, Consultant Chemical Pathologist to the University of Ilorin Teaching Hospital. He has also been External Examiner to several Universities in Nigeria and other African countries, Member of the University Senate, University of Ilorin. Professor Okesina has a good sense of responsibility and leadership. He is efficient, committed, dedicated, resilient, energetic, determined, focused, result-oriented, cool-headed, and very cheerful. He dialogues and consults widely, carrying others along in the process. He is open, courageous, thorough, transparent, accountable and committed to networking, strategizing, observant of due process, judicious use of resources, collective participation and fairness. He respects rules, laws and regulations. He is computer literate and highly committed to tapping the tremendous benefits derivable from ICTProfessor Okesina is a complete gentleman, highly disciplined, kind, considerate and maintains a very cordial relationship with everyone around him. He is popular, highly respected and admired by students, staff and the University authority. His moral standard is beyond reproach.Professor Okesina is happily married with children. He is physically and emotionally stable, positively flexible and morally upright. He is a fair-minded person who interacts across boundaries of religion, ethnicity, profession or any artificial impediments.Based on his academic, professional exposure, administrative experience, leadership records, his integrity, his moral values and his endowment with a distinct vision and mission towards the attainment of global best practices in health care laboratory services, the ACCN at this moment nominate Professor A. B. Okesina to represent Africa on the Executive Board of IFCC.

Kind regards,

Dr Oyetunji. O. SoriyanNational Representative

HEDHILI ABDERRAZEK

ARAB FEDERATION OF CLINICAL BIOLOGY (AFCB)

رئيس التاحادد. كامل محمد حسن

الخرطوم –السودان kamil_mhassan@yahoo.com

الرئيس الفخري للتاحادأ.د.محمد شعرواي

القاهرة–مصر شارع الخليفة المأمون روسكي21

mohamedshaarawy@yahoo.com

نائب رئيس التاحادأ.د. عبد الرزاق الهذيلي

تونسhedili.fam@gnet.tn

الرئيس السابق للتاحادأ.د. العياشي شبراويالمغرب - كازابلنكا

lchabraoui@yahoo.frالمأين العام

أسامة النجار رام ال–فلسطين 1938ص.ب 0097022952181فاكس:

doctor91@hotmail.comأمأين الصندوق

د. تويمي بن جلون كازابلنكا–المغرب

touimibm@gmail.comرئيس اللجنة العلمية:

حداد د. كريستيان بيروت–لبنان

christianhnds@hotmail.com

العأضاء:أ.د. يوسف بلتو

عمان–الردن bilto@ju.edu.joد. عبد الحليم شاشو

الجزائر labochachou@gmail.com

د. عياد عبودليبيا

abuaayad@hotmail.comد. سمير الشرجبي

اليمن wbco@wbco.org

د. عدنان الخطيبسوريا

khatiblab@yahoo.co.ukمصر - د. أسامة منصور

ossamamansour1@hotmail.com

Prof. Abdelrazzaq Hidili Resume,

Professional and academic Actvities Currently, I am :

- Professor of Toxicology at the Faculty of Pharmacy of Monastir andat the Faculty of Medicine of Tunis and health Institues .

- Head of the Biology & Toxicology Laboratories in TunisianPoisoning Control center Centre Mahmoud Yacoub de Medecined'Urgence

- Chair of the Laboratory of Toxicology & Environment researchLR12SP07

- Toxicologist consultant for the Tunisian ministries of Health, SocialAffairs and environment ,Tunisian Environmental Agency ( ANPE) ,Tunisian control Agency (ANCSEP) , Board of Directors INAS(Centre d……)

- Toxicologist expert for many international organizations WHOadvisor (….. , Drugs abuse , ..) OIT ( atmospheric and workPollutens) , Arab Organization of work (pollutens in the workareas ) .

Scientific activities areas As a scientist I 'm:

- the author of 100 published articles,- I 'm the responsable of the Laboratory of Toxicology &

Environment research (50 researchers ) and have supervised morethan 50 researchers (thesis projects ,Masters,…)

- member of many International Journal scientific boards ( reviewers )

My mainly research areas were:- Pesticides, Mycotoxins , Drug abuse, Chemical risks, Trace

elements, Drug monitoring, Environmental pollutants, Bio andChemical hazards.

- Impact of toxic elements on biological and clinical parameters

National , regional and intenational biological responabilities I served as:

- General Secretary (1998-2005) and President of the TunisianSociety of Clinical Biology (2005 -2011)

Tunisia April 10, 2017

Pr Slama HMIDA

President of the Tunisian Society of Clinical Biology

To

Chair of the IFCC Nominations committee

Object : Candidacy of Pr Hedhili Abderrazak to IFCC board

Dear Chair,

On behalf of the Tunisian Society of Clinical Biology (STBC), we are pleased to announce the nominate of the Professor Abderrazek Hedhili for the applications for the election of the IFCC executive Board ( period during 2018 to 2020 ).

Professor Abderrazek Hedhilihas been the general secretary(1999-2005) andpresident of the Tunisian Society of Clinical Biology (2005-2011), he served as Secretary, President, Past President andvice-president (2016- ) of the Arab Federation of Clinical Biology (AFCB), President of the Federation International Francophone de Biologie Clinique et de Medicine du Laboratoire, (FIFBCML) and general secretary and vice-Presidentof Tunisian pharmacists council (since 2011-). Professor Hedhili is the chair of the scientific committee of the Arab Federation of Clinical Biology.

Professor Abderrazek Hedhiliis the author and co-author of 100 published articles and he is responsable ofthe Laboratory of Toxicology & Environment research(50 researchers) and have supervised more than 50 researchers (thesis projects,Masters,…).

Professor Abderrazek hedhiliis member of many International Journal as ascientific board ( rewiever ) .

Professor Hedhili Abderrazek has been actively tothe promotionof Clinical Chemistry and Laboratory Medicine throughout the world and in particular in the Arab countries and in Africa. His research and professional activities have sizable impact on Clinical Chemistry in general and toxicology in particular. He has been designed a smember of the International Scientific Board of IFCC congress

(Berlin 2011 andIstambul2014).

Professor Abderrazek Hedhili activities included the organization of several international (Arab, African and francophone) and national conferences, workshops, symposia and other scientific activities ( since1998) ; in addition he participed to the organization of the Congress of the Arab Federation in Morocco (2000), Tunisia (2004) Syria (2006), Lebanon (2009) and second IFCC Conference (Tunisia Sousse -2004) and FIFBCML Morocco ( 2008) Tunisia 2010.

If he will be elected, Professor Abderrazek Hedhili will be willing to serve for the full three years term of office of the executive board.

During these three years, as the excutive board, Professor Hedhili abderrazek will actively participate and will contribute to the achievement of the IFCC objectives by:

- Encouraging the affiliation of the Arab and all other regional biological societies to the IFCC.

- Encouraging the organisation of a local and regional scientific formations events (workshops, national and regional congress…)

- Helping and encouraging the participation of biologist of Arab and all regional societies in the IFCC events (congress, workshops,…)

- Encouraging the participation of young Scientifics in different IFCC manifestations

- Encouraging the biological research in developing countries with the collaboration of the IFCC experts

- Accompanying and Support the laboratories in developing countries in their efforts to improve the qualities services

- Participing in the standardization and harmonization efforts of laboratory activities

We would be most obliged to consider the election of Professor Abderrazek Hedhili for IFCC executive Board. We believe granting Professor Hedhili this nomination would be a great appreciation, not only for Professor Abderrazek Hedhili, but also for STBC, AFCB & African Biologists.

Pr Slama HMIDA

President of the Tunisian

Society of Clinical Biology

SUNIL SETHI

ASIA - FEDERATION FOR CLINICAL CHEMISTRY AND LABORATORY MEDICINE (APFCB)

c/o Department of Laboratory Medicine National University Hospital

5 Lower Kent Ridge Road Singapore 119074

Tel: (65) 6772 4345 Fax: (65) 6777 1613

http://www.sacb.org.sg

3 March 2017 Dr Bernard Gouget Chairman IFCC Nominations Committee Dear Sir RE: SUNIL SETHI APFCB REGIONAL FEDERATION REPRESENTATIVE OF THE IFCC I seek nomination and consideration for the Asia Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) Regional Representative at the IFCC Executive Board. I confirm that I am willing to serve for the full three year period from 2018-2020, if elected. I certify that I am a member and President of the Singapore Association of Clinical Biochemists (SACB) which is an IFCC Full Member Society. I confirm that I have strong command of both the spoken and written English language. In accordance to the requirements for nomination, I declare that, as candidate for consideration, I have a thorough knowledge of the functioning of the APFCB and being current President, I am able to work in harmony with the APFCB Executive Board and Committee Chairs. If elected, I plan to enhance the scientific and educational activities of the APFCB by supporting and collaborating with IFCC. As the current APFCB President, I will support a renewed MoU between IFCC and APFCB on a broad range of potential activity. Some of my plans for IFCC- APFCB collaboration include the following:

Identify and organise symposia on practice areas of relevance to Clinical Chemistry and Laboratory Medicine in our member countries. I am keen on the areas of laboratory management, automation, biomarker updates and laboratory quality.

Expand the opportunities to disseminate updates, new knowledge and advances in clinical chemistry to members who need them by way of courses.

Identify common technical issues and problems in our region and align recommended solutions and guidelines which have been prepared by IFCC working groups and task force committee reports.

Establish standards for good laboratory practice within the Asia-Pacific region. Engage and facilitate greater involvement of APFCB corporate members and interact in a manner

aligned with IFCC rules of engagement. Participate actively in the programs of the IFCC and seek their support and engagement in APFCB

activities.

c/o Department of Laboratory Medicine National University Hospital

5 Lower Kent Ridge Road Singapore 119074

Tel: (65) 6772 4345 Fax: (65) 6777 1613

http://www.sacb.org.sg

3 March 2017 Dr Bernard Gouget Chairman IFCC Nominations Committee Dear Sir RE: SUNIL SETHI APFCB REGIONAL FEDERATION REPRESENTATIVE OF THE IFCC I seek nomination and consideration for the Asia Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) Regional Representative at the IFCC Executive Board. I confirm that I am willing to serve for the full three year period from 2018-2020, if elected. I certify that I am a member and President of the Singapore Association of Clinical Biochemists (SACB) which is an IFCC Full Member Society. I confirm that I have strong command of both the spoken and written English language. In accordance to the requirements for nomination, I declare that, as candidate for consideration, I have a thorough knowledge of the functioning of the APFCB and being current President, I am able to work in harmony with the APFCB Executive Board and Committee Chairs. If elected, I plan to enhance the scientific and educational activities of the APFCB by supporting and collaborating with IFCC. As the current APFCB President, I will support a renewed MoU between IFCC and APFCB on a broad range of potential activity. Some of my plans for IFCC- APFCB collaboration include the following:

Identify and organise symposia on practice areas of relevance to Clinical Chemistry and Laboratory Medicine in our member countries. I am keen on the areas of laboratory management, automation, biomarker updates and laboratory quality.

Expand the opportunities to disseminate updates, new knowledge and advances in clinical chemistry to members who need them by way of courses.

Identify common technical issues and problems in our region and align recommended solutions and guidelines which have been prepared by IFCC working groups and task force committee reports.

Establish standards for good laboratory practice within the Asia-Pacific region. Engage and facilitate greater involvement of APFCB corporate members and interact in a manner

aligned with IFCC rules of engagement. Participate actively in the programs of the IFCC and seek their support and engagement in APFCB

activities.

c/o Department of Laboratory Medicine National University Hospital

5 Lower Kent Ridge Road Singapore 119074

Tel: (65) 6772 4345 Fax: (65) 6777 1613

http://www.sacb.org.sg

3 March 2017 Dr Bernard GOUGET Chair IFCC Nominations Committee Dear Dr Gouget RE: Nomination of Dr Sunil Sethi as APFCB Regional Representative at the IFCC Executive Board The Singapore Association of Clinical Biochemists (SACB) is pleased to nominate Dr Sunil Sethi as the APFCB Regional Representative on the IFCC Executive Board for the 2018-2020 term of office. Dr Sethi has been the President of the SACB for the past 16 years and has served in various roles in the APFCB for many years. Dr Sethi is the current President of the APFCB. Dr Sethi is a key opinion leader in Clinical Chemistry and Laboratory Medicine. He has an accomplished and outstanding career track record and will contribute actively to the programmes of the APFCB and the IFCC. The SACB is proud and pleased to support and nominate Dr Sethi, the current President of both the SACB and the APFCB, to be the APFCB Regional Representative at the IFCC Executive Board. Sincerely,

Dr Sharon Saw Dr Sunil Sethi

Secretary SACB President SACB and IFCC National Representative

3 March 2017 Dr Bernard Gouget Chairman IFCC Nominations Committee Dear Dr Gouget RE: Nomination of Dr Sunil Sethi as APFCB Regional Representative at the IFCC Executive Board Dr Sethi has a very long standing track record of service to the APFCB and he is the current President of the APFCB. I write in support of Dr Sunil Sethi, who has made the application for the APFCB Regional Representative position at the IFCC Executive Board. Yours sincerely,

Dr Helen Martin Secretary APFCB

3 March 2017 Dr Bernard Gouget Chairman IFCC Nominations Committee Dear Dr Gouget RE: Nomination of Dr Sunil Sethi as APFCB Regional Representative at the IFCC Executive Board Dr Sethi has a very long standing track record of service to the APFCB and he is the current President of the APFCB. I write in support of Dr Sunil Sethi, who has made the application for the APFCB Regional Representative position at the IFCC Executive Board. Yours sincerely,

Dr Dra Endang Hoyaranda Vice-President, APFCB

SVERRE SANDBERG

EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE (EFLM)

Sverre Sandberg Application for the position as IFCC Regional Federations Representative at the Executive Board 2018-2020. Dear colleagues, I am hereby applying for the position of Regional Representative of Europe in the Board of IFCC. The main reason for applying is that I through long experience in IFCC and EFLM and scientific and organisational work in general think that I have a good background and knowledge to be able to represent the European region in IFCC.

In addition, according to the EFLM procedure for electing the Regional representative, the EFLM Executive Board proposed me to act as EFLM Representative in the IFCC Executive Board, to serve in this position from January 1th 2018 to December 31th 2020, This proposal has been endorsed by the National Societies of EFLM. I think I have reasonable good command of written and spoken English – although it can certainly be improved. A short review of my work in IFCC and EFLM I started in IFCC in 1996 by establishing a Committee for Evidence Based Laboratory Medicine. At that time this was a completely new topic that in later years has gained a lot of interest. As chair of this committee and later as an expert consultant, I had the privilege to write scientific papers and to give courses and lectures about this topic all over the world.

After finishing my terms as chair of the Committee for Evidence Based Laboratory Medicine, I chaired from 2002 the Task Force for The Global Campaign of Diabetes Mellitus in IFCC coordinating the different “diabetes” activities in IFCC. This was again a great challenge.

In 2009 I was asked to chair the Scientific Committee of EFLM. As a new organisation, it has been fascinating to take part in the establishment of different working groups in EFLM. EFLM now has 8 different working groups. It has been important for EFLM not to overlap with the scientific work IFCC is doing, and many of the working groups established deal with topics in the laboratory/clinical interface and with the pre- and postanalytical phases. I was allowed to be the chair of the Scientific Programme Committee of the 1th European Joint Congress of EFLM-UEMS, Laboratory Medicine at the Clinical Interface in Lisbon, in 2010. I have also participated in other WGs in EFLM and IFCC and been on the Scientific Programme Committees for many of the last Euromedlab meetings.

In 2014-2015 I was president elect of EFLM and in 2016-2017 president of EFLM. A short review of my professional work in Norway One of the achievements that I think have been useful is the establishment of the organisation The Norwegian Quality Improvement of Laboratory Examinations, NOKLUS. I participated in the founding of this organisation in 1992 and have been (and is) its first Director. The organisation has now grown to about 100 employees and is unique since it mainly deals with laboratory activity in primary care, including GPs offices, nursing homes, oil platforms etc. From 2017 the EQA organisation for hospital laboratories merged with Noklus and the organisation changed name to Norwegian Quality Improvement of Laboratory Examinations. Regular EQA schemes for the participants are established and laboratory consultants give advice to the participants. It is voluntarily to participate, but 99.8% of GPs, 92% of nursing homes and all hospital laboratories participate in the

organisation, altogether about 3100 participants. The Norwegian Diabetes Registry is part of NOKLUS and has been partner in two EU projects. In 1999 the Norwegian Porphyria Centre, NAPOS, was established, and I have been in the lead of this since the establishment. The centre diagnoses all porphyria patients in Norway, and gives advice to health care and patients concerning e.g. diagnosis, treatment and follow up. The centre has also established a drug database for unsecure drugs for these patients. The database is used worldwide. The Centre is also running an EQAS for specialist porphyria laboratories worldwide. The centre has established a National Porphyria Registry and is also responsible for the European Porphyria Registry. It is in the lead together with Cardiff, Paris and Sweden of a EU project. As Director of Laboratory of Clinical Biochemistry at Haukeland University Hospital, (250 employees) in 10 years from 2002-12, I participated in the 15189 accreditation process and has worked to make the specialist in laboratory medicine more “clinically” visible so that they e.g. participate with clinicians in setting up guidelines on what routine laboratory tests to be requested for what conditions. EQAS is a large part of what I have been dealing with, and I have been on the Board and have been president of the European Organization for External Quality Assurance Providers in Laboratory Medicine (EQALM). My main research interests are in the use and interpretations of laboratory tests, external quality control, porphyrias, photobiology, evidence based laboratory medicine, post-analytical quality assurance and laboratory use in diabetes mellitus. More than 250 papers in peer reviewed journals and 5 book chapters have been published. I have been the main supervisor of 14 PhD students. I have given lectures and chaired symposiums on every large IFCC or EFLM conference the last 20 years. In average 10-15 international lectures every year. I have received 7 international awards.

My role as Regional Federation Executive

I think that with my background from both IFCC and EFLM I know the organisations rather good. I welcome the reorganisation of the EB of IFCC so that the EB has representatives from all the different regions. In the future, it will be important to find a balance of what should be done by the Regional Federations and what should be done by IFCC. It is important to market our discipline and to have a close contact with both clinicians and industry. EFLM and IFCC are organisations that can bring people together from different parts of Europe and the world to make outstanding scientific and professional achievements and to work together in a friendly and accepting atmosphere. At the same time IFCC must be a strong organisation to form our profession in the world and to cooperate with clinical and laboratory organisations worldwide.

I will represent the European Region and see that it will have a strong and important role in IFCC.

Bergen May 20th 2017 Sverre Sandberg Attached is a short CV and a publication list

Bergen 24.05.2017 CURRICULUM VITA SVERRE SANDBERG Work experience Present positions 1. Director (from 1996) of the Norwegian Quality Improvement og Laboratory Examinations (NOKLUS), Bergen (budget 84 mill NOK) including the Norwegian Diabetes Registry for Adults (www.noklus.no). 2. Director Norwegian Porphyria Centre, Haukeland University Hospital, Bergen www.napos.no (budget 8 mill NOK) 3. Professor at the Institute of Global Health and Primary Health Care, Univeristy of Bergen Earlier position 1. Director Laboratory of Clinical Biochemistry, Haukeland University Hospital from 2003-2012 Some other ”non-paid” positions 1. President EFLM (European Federation of Clinical Chemistry and Laboratory Medicine) from 2016-2017 2. Member of steering group European Porphyria Network, EPNET, A European Union Project from 2011 3. Partner in EUBIRO I and II, EUropean Best Information through Regional Outcomes in Diabetes" (EUBIROD) 2009-12,

EU financed projects. 4. Chair Scientific Committee for 1th EFCC, UEMS kongress i Lisbon 2010 (1500 part) 5. Chair Scientific Division in EFLM (European Federation of Clinical Chemistry) from 2009 – 2014 6. President elect in EFLM 2014-16 7. President of the External Organisation for External Quality Assurance Providers in Europe (EQALM) 2012-2014 8. Chair WG for Postanalytical external quality assurance (WG-PEQAS) in EFLM 2010-2013 9. Steering group member in ”Quality in the spotlight”, Antwerpen, fra 2005 10. Member WG-test evaluation (WG-TE) in EFLM fra 2010 11. Member IFCC WG for POC instruments from 2010 12. Chair Task and Finish group Biological Variation Database in EFLM 13. Member of Scientific committee for several European meetings (Euromedlab Milan (5000 participants) Euromedlab in

Paris 2015 (4000 part), EFLM-UEMS conference in Dubrovnik 2012 (1500 participants), Worldlab 2016 in Durban. 14. Editor in The Scandinavian Journal of Clinical and Laboratory Investigation, from 1995 Supervisor Former main supervisor for 14 PhDs (9 after 2010) Present main supervisor for 3 PhD students Supervision of master degrees and the work as assistant supervisor of PhDs have not been registered. Total number of peer reviewed publications: 257 Peer reviewed publications from 2012 – 2017 May 1. Stavelin A, Meijer P, Kitchen D, Sandberg S. External quality assessment of point-of-care International Normalized

Ratio (INR) testing in Europe. Clin Chem Lab Med. 2012;50:81–8. 2. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, et al. [The actual issues of measurement and

presentation of results of albumin excretion with urine]. Klin Lab Diagn. 2012;:43–53. 3. Aakre KM, Oosterhuis WP, Sandberg S. How do laboratory specialists advise clinicians concerning the use and

interpretation of renal tests? Scandinavian journal of clinical and laboratory investigation. 2012;72:143–51. 4. Kjome RLS, R oraas T, Gran r a s AG, Sandberg S. Regional differences in sales of glucometer strips and antidiabetics.

Tidsskr Nor Laegeforen. 2012;132:1453–6. 5. Bjørke-Monsen A-L, Torsvik IK, Ueland PM, Sætran HA, Sandberg S. Increased yet iron-restricted erythropoiesis in

postpartum mothers. Ann Hematol. 2012;91:1435–41. 6. Kristoffersen A-H, Thue G, Ajzner E, Claes N, Horvath AR, Leonetti R, et al. Interpretation and management of INR

results: a case history based survey in 13 countries. Thromb Res. 2012;130:309–15. 7. Røraas T, Petersen PH, Sandberg S. Confidence intervals and power calculations for within-person biological variation:

effect of analytical imprecision, number of replicates, number of samples, and number of individuals. Clin Chem. 2012;58:1306–13.

8. Sølvik UØ, Røraas TH, Petersen PH, Stavelin AV, Monsen G, Sandberg S. Effect of coagulation factors on discrepancies

in International Normalized Ratio results between instruments. Clin Chem Lab Med. 2012;50:1611–20. 9. Aakre KM, Watine J, Bunting PS, Sandberg S, Oosterhuis WP. Self-monitoring of blood glucose in patients with

diabetes who do not use insulin - are guidelines evidence-based? Diabet Med. 2012;29:1226–36. 10. Lippi G, Becan-McBride K, Behúlová D, Bowen RA, Church S, Delanghe J, et al. Preanalytical quality improvement: in

quality we trust. Clin Chem Lab Med. 2012;0:1–13. 11. Van Houcke SK, Rustad P, Stepman HCM, Kristensen GBB, Stöckl D, Roraas TH, et al. Calcium, magnesium, albumin,

and total protein measurement in serum as assessed with 20 fresh-frozen single-donation sera. Clin Chem. 2012;58:1597–9.

12. Kristoffersen A-H, Petersen PH, Sandberg S. A model for calculating the within-subject biological variation and likelihood ratios for analytes with a time-dependent change in concentrations; exemplified with the use of D-dimer in suspected venous thromboembolism in healthy pregnant women. Ann Clin Biochem. 2012;49:561–9.

13. Tollånes MC, Aarsand AK, Villanger JH, Støle E, Deybach J-C, Marsden J, et al. Establishing a network of specialist Porphyria centres - effects on diagnostic activities and services. Orphanet J Rare Dis. 2012;7:93.

14. Elder G, Harper P, Badminton M, Sandberg S, Deybach J-C. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013, 36: 849-57

15. Stavelin A, Petersen PH, Sølvik UØ, Sandberg S. External Quality Assessment of Point-of-Care Methods: Model For Combined Assessment of Method Bias and Single-Participant Performance by the Use of Native Patient Samples and Noncommutable Control Materials. Clin Chem. 2013;59:363–71.

16. Tirimacco R, Koumantakis G, Erasmus R, Mosca A, Sandberg S, Watson ID, et al. Glucose meters - fit for clinical purpose. Clin Chem Lab Med. 2013;:1–10.

17. Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 2013;4:12.

18. Cooper J, Thue G, Claudi T, Løvaas KF, Carlsen S, Sandberg S. The Norwegian Diabetes Register for Adults - an overview of the first years. Norsk Epidemiologi. 2013;23:29–34.

19. Bustad HJ, Vorland M, Rønneseth E, Sandberg S, Martinez A, Toska K. Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria. Biosci Rep. 2013. 33 / art:e00056 / doi 10.1042/BSR20130045

20. Carobene A, Braga F, Røraas T, Sandberg S, Bartlett WA. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and γ-glutamyl transferase. Clin Chem Lab Med. 2013;51:1997–2007.

21. Cooper JG, Claudi T, Thordarson HB, Løvaas KF, Carlsen S, Sandberg S, et al. Treatment of type 1 diabetes in the specialist health service - data from the Norwegian Diabetes Register for Adults. Tidsskr Nor Laegeforen. 2013;133:2257–61.

22. Sølvik UØ, Røraas T, Christensen NG, Sandberg S. Diagnosing diabetes mellitus: performance of hemoglobin A1c point-of-care instruments in general practice offices. Clin Chem. 2013;59:1790–801.

23. Aakre KM, Røraas T, Petersen PH, Svarstad E, Sæle K, Sandberg S. Week-to-week biological variation in the N-terminal prohormone of brain natriuretic peptide in hemodialysis patients and healthy individuals. Clin Chem. 2013;59:1813–4.

24. Watine J, Mokaddem W, Carriere P, Couaillac J-P, Kristoffersen A-H, Thue G, et al. Heterogeneity in the handling of vitamin-K-antagonists and of INR: the example of Quercy-Rouergue. Ann Clin Biochem. 2013;71:707–16.

25. Kristensen GBB, Moberg Aakre K, Kristoffersen A-H, Sandberg S. How to conduct External Quality Assessment Schemes for the pre-analytical phase? Biochemia Medica. 2014;24:114–22.

26. Horvath AR, Lord SJ, Stjohn A, Sandberg S, Cobbaert CM, Lorenz S, et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta. 2014;427:49–57.

27. Robinson MK, Caudill SP, Koch DD, Ritchie J, Hortin G, Eckfeldt JH, et al. Clinica Chimica Acta. Clinica Chimica Acta. 2014;431:40–5.

28. Mykletun M, Aarsand AK, Støle E, Villanger JH, Tollånes MC, Baravelli C, et al. Porphyrias in Norway. Tidsskr Nor Laegeforen. 2014;134:831–5.

29. Aarsand AK, Sandberg S. How to achieve harmonisation of laboratory testing -The complete picture. Clin Chim Acta. 2014;432:8–14.

30. Aakre KM, Røraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg Ø, et al. Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clin Chem. 2014;60:838–47.

31. Andreassen LM, Sandberg S, Kristensen GBB, Sølvik UØ, Kjome RLS. Nursing home patients with diabetes: Prevalence, drug treatment and glycemic control. Diabetes Res Clin Pract. 2014;105:102–9.

32. Sølvik UØ, Røraas T, Petersen PH, Stavelin A, Monsen G, Sandberg S. The influence of coagulation factors on the in-treatment biological variation of international normalized ratio for patients on warfarin. Scandinavian journal of clinical and laboratory investigation. 2014;74:470–6.

33. Lenters-Westra E, Røraas T, Schindhelm RK, Slingerland RJ, Sandberg S. Biological variation of hemoglobin a1c: consequences for diagnosing diabetes mellitus. Clin Chem. 2014;60:1570–2.

34. Bukve T, Røraas T, Riksheim BO, Christensen NG, Sandberg S. Point-of-care urine albumin in general practice offices: effect of participation in an external quality assurance scheme. Clin Chem Lab Med. 2015;53:45–51.

35 Andersen J, Gjengedal E, Sandberg S, Råheim M. A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda. Br J Dermatol. 2015; 172:223-9

36. Aarsand AK, Røraas T, Sandberg S. Biological variation - reliable data is essential. Clin Chem Lab Med. 2015;53:153–4. 37. Ajzner E, Rogic D, Meijer P, Kristoffersen A-H, Carraro P, Sozmen E, et al. An international study of how laboratories

handle and evaluate patient samples after detecting an unexpected APTT prolongation. Clin Chem Lab Med. 2015. 10.1515/cclm-2014-1183

38. Bartlett WA, Braga F, Carobene A, Coskun A, Prusa R, Fernandez-Calle P, et al. A checklist for critical appraisal of studies of biological variation. Clin Chem Lab Med. 2015;53:879–85.

39. Oosterhuis WP, Sandberg S. Proposal for the modification of the conventional model for establishing performance specifications. Clin Chem Lab Med. 2015;53:925–37.

40. Panteghini M, Sandberg S. Defining analytical performance specifications 15 years after the Stockholm conference. Clin Chem Lab Med. 2015;53:829–32.

41. Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oosterhuis W, et al. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2015;53:833–5.

42. Sølvik UØ, Risa M, Jacobsen CE, Monsen G, Sandberg S. Performance of 10 systems for self-monitoring of blood glucose by trained healthcare professionals and in the hands of the users. Clin Chem. 2015;61:772–4.

43. Thue G, Sandberg S. Analytical performance specifications based on how clinicians use laboratory tests. Experiences from a post-analytical external quality assessment programme. Clin Chem Lab Med. 2015;53:857–62.

45. Horvath AR, Bossuyt PMM, Sandberg S, John AS, Monaghan PJ, Verhagen-Kamerbeek WDJ, et al. Setting analytical performance specifications based on outcome studies - is it possible? Clin Chem Lab Med. 2015;53:841–8.

46. Panteghini M, Sandberg s. Total error vs. measurement uncertainty: the match continues. Clin Chem Lab Med. 2016 Feb 1;54(2):195-6

47. Løvaas KF, Cooper JG, Sandberg S, Røraas T, Thue G. Feasibility of using self-reported patient data in a national diabetes register. BMC Health Serv Res. 2015 Dec 15; 15(1):553

48. Andersen J, Nordin K, Sandberg S. Illness Perception and Psychological Distress in Persons with Porphyria Cutanea Tarda. Acta Derm Venereol. 2016 Jan 18. Doi:10.2340/00015555-2339 [Epub ahead of print]

49. Carlsen s, Skrivarhaug T, Thue G, Cooper JG, Gøransson L, Løvaas K, Sandberg S. Glycemic control and complications in patients with type 1 diabetes – a registry-based longitudinal study of adolescents and young adults. Pediatr Diabetes 2016 Feb 15. Doi:10.1111/pedi.12372. [Epub ahead of print]

50. Stavelin A, Riksheim BO, Christensen NG, Sandberg S. The Importance of Reagent Lot Registration in External Quality Assurance/Proficiency Testing Schemes. Clin Chem. 2016;62:708–15.

51. Roraas T, Stove B, Hyltoft Petersen P, Sandberg S. Biological Variation: The Effect of Different Distributions on Estimated Within-Person Variation and Reference Change Values. Clin Chem. 2016, 62; 725-36

52. Kristoffersen A-H, Ajzner E, Rogic D, Sozmen EY, Carraro P, Faria AP, Sandberg S. Is D-dimer used according to clinical algorithms in the diagnostic work-up of patients with suspicion of venous thromboembolism? A study in six European countries. Thromb Res. 2016;142:1–7.

53. Carobene A, Strollo M, Jonker N, Barla G, Bartlett WA, Sandberg S, et al. Sample collections from healthy volunteers for biological variation estimates' update: a new project undertaken by the Working Group on Biological Variation established by the European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry and Laboratory Medicine. 2016, in press.

54. Monaghan PJ, Lord SJ, John AS, Sandberg S, Cobbaert CM, Lennartz L, Verhagen-Kamerbeek WJ, Ebert C, Bossuyt PMM, Horvath AR. Biomarker development targeting unmet clinical needs. Clinica Chimica Acta. 2016;460:211–9.

55. Bukve T, Stavelin A, Sandberg S. Effect of Participating in a Quality Improvement System over Time for Point-of-Care C-Reactive Protein, Glucose, and Hemoglobin Testing. Clin Chem. 2016, in press, 10.1373/clinchem.2016.259093

56. Ceriotti F, Fernandez-Calle P, Klee GG, Nordin G, Sandberg S, Streichert T, et al. Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. Clinical Chemistry and Laboratory Medicine. 2017;55:189–94.

57. Cadamuro J, Simundic A-M, Ajzner E, Sandberg S. A pragmatic approach to sample acceptance and rejection. Clinical Biochemistry. 2017. 10.1016/j.clinbiochem.2017.02.001

58. Kristoffersen AH, Petersen PH, Roraas T, Sandberg S. Estimates of Within-Subject Biological Variation of Protein C, Antithrombin, Protein S Free, Protein S Activity, and Activated Protein C Resistance in Pregnant Women. Clin Chem. 2017; 10.1373/clinchem.2016.265900

59. Stavelin A, Sandberg S. Essential aspects of external quality assurance for point-of-care testing. Biochemia Medica. 2017;27:81–5.

60. Cadamuro J, Mrazek C, Haschke-Becher E, Sandberg S. To report or not to report: a proposal on how to deal with altered test results in hemolytic samples. Clinical Chemistry and Laboratory Medicine. 2017. Pubmed: 28207409

61. Lippi G, Baird GS, Banfi G, Bölenius K, Cadamuro J, Church S, et al. Improving quality in the preanalytical phase through innovation, on behalf of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE). Clinical Chemistry and Laboratory Medicine. 2017;55: 489-900

62. Røraas T, Støve B, Petersen PH, Sandberg S. Biological variation: Evaluation of methods for constructing confidence intervals for estimates of within-person biological variation for different distributions of the within-person effect. Clin Chim Acta. 2017 in press.

63. Carobene A, Røraas T, Sølvik UØ, Sylte MS, Sandberg S, Guerra E, et al. Biological Variation Estimates Obtained from 91 Healthy Study Participants for 9 Enzymes in Serum. Clin Chem. 2017, in press

64 Panteghini M, Adeli K, Ceriotti F, Sandberg S, Horvath AR. American Liver Guidelines and Cutoffs for “Normal” ALT: A Potential for Overdiagnosis. Clin Chem. 2017, in press

Book chapters after 2012 1. Sandberg, S. Putting Point of Care Testing into Context: Moving Beyond Innovation to Adoption. In: Price, CP, St John, A,

Kricka,LL, eds. Point of care Testing, Needs, Opportunity and Innovation. Washington DC: AACC Press; 2010 2. Kristensen GBB, Aakre KM, Kristoffersen AH, Sandberg S. External Quality Assurance for the Preanalytical Phase1 In

Guder, WG ed. Pre-Examination Procedures in Laboratory Diagnostics. Preanalytical Aspects and their Impact on the Quality of Medical Laboratory. Results Berlin: DeGruyter 2015. ISBN: 978-3-11-033404-3

3. Fraser C and Sandberg S. Biological variation. In Rifai N, Horvath R eds Tietz textbook of Clinical Chemistry and Molecular Biology. 6t edition NewYork Elsevier 2017

4. Miller G and Sandberg S. Quality Control of the Analytical Examination Process. In Rifai N, Horvath R eds Tietz textbook of Clinical Chemistry and Molecular Biology. 6t edition NewYork Elsevier 2017

Lectures In average 10-15 International lectures per year the last 20 years

President Lutz Schwettmann Secretary Joakim Eikeland Treasurer Karin Toska Web Editor Gunhild Garmo Hov National representative Anne Lise Bjørke Monsen Education and Training Bente Fjeld Head Office Ålesund Hospital Dep. of Medical Biochemistry 6026 Ålesund Norway Tel. +47 7010 5624

Dr. Bernard Gouget

Chair, Nominations Committee

IFCC

Acceptance by nominee

I accept the nomination for election to the position of Regional

Representative of EFLM at the IFCC Executive Board and the

obligations and time commitment required for this position, if

elected.

My contact details are:

Address: Norwegian Quality Improvement Laboratory Examinations, Noklus Haraldsplass Deaconess Hospital Bergen Norway Phone: +47 5558 6706 Email: sverre.sandberg@noklus.no

Signature: Date: 26th April 2017

ROSA SIERRA-AMOR

LATIN-AMERICAN CONFEDERATION OF CLINICAL BIOCHEMISTRY (COLABIOCLI)

Dr. Sierra-Amor Short CV

Representative of Regional Federation 2018-2020

Rosa Isabel SIERRA-AMOR, MSc. PhD Cell: +521-2299842293 Email: rosa.sierra.amor@gmail.com Skype: sierrarosa2016@outlook.com

Dr Sierra-Amor is a Clinical Biochemist graduated from the National

Autonomous University of Mexico, UNAM, with a Masters and Doctoral degree in Physiology Sciences at the Biomedical Research Institute of the Postgraduate Studies, UNAM, she did a fellowship at the Jewish Hospital Medical Centre in St Louis Mo. US (1982), and a post-training course in clinical chemistry at the University of Reading, England (1986). From 1980-1990, she coordinated the laboratory at the Department of Nephrology and Mineral Metabolism at the Medical Sciences and Nutrition Hospital Salvador Zubirán in México city, where she established the assays for parathyroid hormone, and vitamin D metabolites among others. In late 1990, she was invited to direct the Calcium Research Laboratory, Department of Paediatrics, Division of Neonatology, University of Cincinnati, Ohio, which later on became to be the Core Laboratory in Bone and Mineral Metabolism at Cincinnati Children´s Hospital Medical Centre (1990-2003). After her return to Mexico, she has served as board member of the Laboratory LAQUIMS, S.C. in Veracruz, Mexico, managing the quality system department. At the Mexican Accreditation Entity, she was member of the Executive Board (2006-2007), member WG in clinical laboratory (2004-2008), and Member Subcommittee on Laboratory Accreditation (2009-2011). Since 2008, she is a member of Mexican Council of Board Certification in Clinical Biochemistry. She was founder and first president of the Mexican Association of Clinical Laboratory Sciences, CMCLC, contributing to the bases of the actual society integrated by highly qualified clinical chemists and researches from several universities along the country. She created the Students Chapters to motivate young scientists in laboratory medicine for the future of the profession. During her first and second term of office she consolidated the association and signed agreements of mutual collaboration with several other organizations, e.g. in accreditation, clinical biochemistry, and give auspices to industry courses in different fields of laboratory medicine.

Other activities included speaker of national, regional, international congresses, three books chapters, author and co-author of several scientific articles, one hundred poster presentations, and professor of national and international courses of post-graduated programs in Laboratory Medicine.

Dr. Sierra-Amor Statement

Representative of Regional Federation 2018-2020

Mexico City, May 30th, 2017 IFCC Office Attention: Mrs Paola Bramati Re: Regional Federation Representative

It will be a great honour for me to serve as Regional Federation Representative for the term 2018-2020, if elected. I am aware of the importance of service that is required, as well as the responsibility of holding a position in IFCC representing a Regional Federation.

As Member EB COLABIOCLI (2016-2017), I have reinforced COLABIOCLI

in understanding how to develop stronger tides with IFCC. The experience achieved serving IFCC through the years has allowed me to enhance the activities and communication with COLABIOCLI member societies, regional industry, other international organizations, research institutions, universities and accreditation bodies.

If elected, one of my main objectives would be to promote IFCC activities in

COLABIOCLI and vice verse. Language barriers should not be a problem, if COLABIOCLI affiliated member societies and IFCC learn from each other how to promote the profession regional and world-wide.

If elected, as Regional Federation Representative, I will improve the

relationship with other regions, universities, and accreditation bodies, promoting harmonization and standardization projects, e-learning courses and young scientist training programs.

Sincerely,

Rosa Isabel Sierra-Amor, MSc, PhD

CONFEDERACIÒN LATINOAMERICANA DE BIOQUÌMICA CLÌNICA

Ejido 1589 CP 11100 Montevideo, Uruguay

Teléfono: (+598) 29006340

Web: www.colabiocli.com mail: colabiocli2016@gmail.com

Nota 30/2017

Montevideo, June 29, 2017

Dear Chair of the Nominations Committee, Dr. Bernard Gouget

On behalf of the Executive Committee of COLABIOCLI, I wish to support the nomination of Dr. Rosa Isabel SIERRA AMOR to the position of Representative of our Regional Federation, the Latin American Confederation of Clinical Biochemistry (COLABIOCLI) in the IFCC Board

Dr. Rosa Sierra is a very active member of the Executive Committee of COLABIOCLI (2016-2017). During this period she has been a great support to improve our ties with the IFCC. This has been fostered by the vast experience acquired by the applicant during numerous instances occupying important positions into the IFCC Executive Committee, as well as its divisions, WG, TF, etc.

I would like to emphasize Dr. Sierra's enormous vocation of service and sense of solidarity towards the Latin American countries that require her guidance and help. That has resulted in the fact that she is a very popular and appreciated figure in our region.

For these reasons I believe that this candidacy is an excellent option to have the collaboration of one of the main Latin-American leaders in the Board of IFCC

Sincerely yours

Dra Graciela Queiruga,

President of COLABIOCLI (2016-2017),

Asociación Bioquímica Uruguaya Filial de la Asociación de Química y Farmacia del Uruguay Miembro de la International Federation of Clinical Chemistry (IFCC) Afiliada a la Confederación Latinoamericana de Bioquímica Clínica (COLABIOCLI)

Montevideo, June 29, 2017 Dear Chair of the Nominations Committee, Dr. Bernard Gouget

On behalf of the Asociación Bioquímica Uruguaya, I wish to support the nomination of Dr. Rosa Isabel SIERRA AMOR to the position of Representative of our Regional Federation, the Latin American Confederation of Clinical Biochemistry (COLABIOCLI). Dr. Rosa Sierra is very important colleague whose first contact with Uruguay was in 1989 lecturing several topics during the course of Continuous Improvement of Quality leaded by the Mexican National Society. In a second opportunity she came to Uruguay to lecture a course of Calcium Metabolism with the support of the Continuous Education Program of the University. In addition she was co-tutor of one Uruguayan Postgrad student on this topic, who was received in her lab in the Cincinnati Hospital, and thanks to her has achieved the PhD title. Subsequently, she continued her dynamic contacts with Uruguay as a facilitator link between our National Society and IFCC. Concluding, Dr. Sierra has been playing a very important role in the Academic Uruguayan world. We know that she has been acting in this way with all countries that needed her help, so this position is a just recognition to her achievements Those are the reasons why I consider Dr. Sierra is one of the best candidates for this position Sincerely yours

QF. Fernando Antunez President of Asociacion Bioquímica Uruguaya

Ejido 1589 – Montevideo – Uruguay E-mail: secretaria.abu@gmail.com Telefax: (598) 29006340 – 29030711

Página 1 de 1

Mexico City, June 28th, 2017 IFCC Office Attention: Mrs Paola Bramati Re: Representative of Regional Federation. On behalf of the Executive Committee Board of the Mexican Association of Clinical Laboratory Sciences (CMCLC), I would like to nominate Dr. Rosa Isabel SIERRA AMOR, MSc, PhD for the position of Representative of our Regional Federation, the Latin American Confederation of Clinical Biochemistry (COLABIOCLI). She has contributed extensivelly promoting the profession among IFCC membership in the region, lecturing and inviting colleagues to participate actively in IFCC. She was elected Member of the COLABIOCLI Executive Committee last year, position that she has managed efficientely since then, therefore, we considered the best candidate to be nominate for this position. Attached is a short curriculum vitae of Dr Sierra-Amor. And her signed statement confirming that she is willing to be nominated, and to serve for the full three years term of office of the IFCC Executive Board if elected. Dr Sierra-Amor has a good command of written and spoken English, she has served in several occasions at different IFCC TF, WG, Committees, and EB and as EB Liaison with Divisions. She is also including an explanation on how she will discharge the role of Regional Federation Executive, if elected. In case of any question, please do not hesitate to contact me or our National Representative, Dr Francisco Muñoz-Valle. Sincerely Yours,

Ma. Jezabel Vite-Casanova, ME President CMCLC (2017-2018) CC: COLABIOCLI President, IFCC National Representative, and Dr. RI Sierra-Amor

ANN M. GRONOWSKI

NORTH AMERICAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATIORY MEDICINE (NAFCC)

Ann M. Gronowski, Ph. D.Phone: 314-362-0194

Fax: 314-362-1461E-mail: gronowski@wustl.edu

Bernard Gouget, PhDChair IFCC Nominating Committee

July 12, 2017

Dear Professor Gouget:

I am honored to be considered for the position of 2018-2020 IFCC North American Federation forClinical Chemistry (NAFCC) Executive Board Member.

If selected, I would strive to represent the NAFCC at the IFCC executive board meetings and projectthe North American perspective in IFCC deliberations. I feel I am uniquely qualified for this role as Ihave been actively involved with the AACC for 23 years and with the IFCC for 17 years and havegreatly enjoyed my roles with both organizations. I feel I understand both organizations and can helpIFCC achieve its goals while representing the interests of the NAFCC.

I am committed to attending IFCC executive board meetings and additional required meetings as they arise (such as the General Conference) for the years 2018-2020.

I look forward to serving the NAFCC and the IFCC. Please let me know if I can provide anyadditional information.

Sincerely,

Ann M. Gronowski, Ph.D.Professor of Pathology & Immunologyand Obstetrics & Gynecology

CURRICULUM VITAE

Ann M. Gronowski, Ph.D.

Date: May, 2017

Citizenship: U.S.A.

Address and Telephone Numbers:

(Office) Department of Pathology & Immunology Washington University School of Medicine 660 South Euclid Avenue, Box 8118 St. Louis, Missouri 63110 (314) 362-0194 (FAX: 314-362-1461) E-mail: gronowski@wustl.edu

Present Position: Professor of Pathology & Immunology and Obstetrics & Gynecology, Division of Laboratory Medicine, Washington University, St. Louis, MO

Associate Medical Director, Clinical Chemistry, Serology and Immunology, Barnes-Jewish Hospital, St. Louis, MO

Education:

1985 B.S., Animal Science, University of Illinois, Urbana, IL1988 M.S., Nutrition, Iowa State University, Ames, IA1992 Ph.D., Endocrinology and Reproductive Physiology, University of Wisconsin, Madison, WI

Current Academic Position/Employment:

2003-present Co-Director, Postdoctoral Training Program in Clinical Chemistry (ComACC Approved Program)

2011-Present Professor of Pathology and Immunology, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, Missouri

2011-Present Professor of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri

Medical Licensure and Board Certification:

1998 American Board of Clinical Chemistry (Certificate #924)

Brief List of Honors and Awards:

2010 Outstanding Contributions through Service to the Profession of Clinical Chemistry Award, AACC

2011 Washington University Clinical Pathology Teaching Award2011 Mentorship Award, Society of Young Clinical Laboratorians, AACC2013 Bernard F. Gerulat Memorial Award, AACC New Jersey Section 2015 Distinguished Educator-Clinical Fellow Mentoring Award, Washington

University School of Medicine2016 Outstanding Contributions through Education Award, AACC2016 Achievement Award, Pediatric Maternal Fetal Division, AACC2016 Kubasic Lectureship Award Winner, AACC Upstate New York Local Section

Editorial Responsibilities:

2000-2006 Board of Editors, Clinica Chimica Acta2007- present Board of Editors (Clinical Case Study Co-editor), Clinical Chemistry

2008-2011 Associate Editor Tietz Textbook of Clinical Chemistry and Molecular Diagnostics

2011- 2014 Section Editor, Clinical Chemistry Trainee Council www.traineecouncil.org 2013-2014 Guest Editor, Special issue on Women’s Health, Clinical Chemistry, January 20142014 Editor-in-Chief, AACC Clinical Laboratory News Dailies, July 20142014-present Co-Chair, Clinical Chemistry Trainee Council www.traineecouncil.org

Brief List of Professional Societies and Organizations:

1994-2013 American Association for Clinical Chemistry (AACC) National Awards Committee, Chair, 1999-2002 2000 Annual Mtg Organizing Committee, Plenary Coordinator, 1999-2000 Meetings Taskforce 1999-2000 National Nominating Committee, 2000 National Nominating Committee, Chair, 2001 2005 Annual Meeting Organizing Committee, Vice Chair 2001-2005 Board of Directors, 2003-2005 Annual Meeting Taskforce, 2003-2004 Young Clinical Chemists Advisory Group, 2003-2004

Society for Young Clinical Laboratorians, Senior Advisor, 2004-2005 and 2007-2009

Board of Trustees, Van Slyke Foundation, 2006-2009 2008 Annual Meeting Organizing Committee, Chair, 2006-2008 Meetings Management Group, 2006-2009 Chair, Student Poster Contest 2005-present

Treasurer, 2007-2009 Annual Meeting Focus Group, 2008 President-Elect, 2010 Awards Task Force, 2010 Annual Meeting Task Force, 2010 President, 2011

Executive Vice President search Committee, 2011Past-President 2012Board of Trustees, Van Slyke Foundation, 2013Nominating committee, 2014-2015Governance Review Advisory Task Force, 2014-20152017 Annual Mtg Organizing Committee, Plenary Coordinator, 2016-2017

1998-2004 American Board of Clinical Chemistry (ABCC) Clinical Chemistry Exam Subcommittee, Member, 1998-2001 Clinical Chemistry Exam Subcommittee, Co-Chair, 2001-2002 Molecular Pathology Exam Committee, Member, 1998-2001 Vice-President and Chair, Examinations Committee, 2002-2003 President, 2003-20042000-2012 International Federation of Clinical Chemistry and Laboratory Medicine Awards Committee, 2000-2002 National Representative for AACC, 2010-2012 Chair, Task Force on Ethics, 2014-present2003-2009 Commission on Accreditation in Clinical Chemistry (ComACC) Secretary/Treasurer, 2003-20092013-2015 Clinical Laboratory Standards Institute (CLSI) Consensus Committee on Clinical Chemistry and Toxicology2015-2016 Clinical Laboratory Improvement Advisory Committee (CLIAC), Centers for

Disease Control